Epigene Labs

About:

Epigene Labs designs genomics-driven drug for precision oncology.

Website: http://www.epigenelabs.com/

Twitter/X: epigenelabs

Top Investors: European Innovation Council, Daphni, AGORANOV, Majycc eSanté Invest

Description:

Over the past couple of decades, the exponential progress of sequencing technologies has allowed an increasing number of cancer patients to benefit from precision oncology. However, the aggregation, analysis, and visualization of the massive amounts of genomic data remain a major challenge for precision oncology expansion. The Epigene Labs technology platform enables cancer drug hunters to seamlessly leverage advanced artificial intelligence in transforming genomic data into actionable insights for designing precision oncology approaches. With R&D in Paris and business development in Boston, Epigene Labs operates in the setting of value-based partnerships with world leading cancer centers and high-profile biotechs.

Total Funding Amount:

5.4M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Paris, Ile-de-France, France

Founded Date:

2019-01-01

Contact Email:

contact(AT)epigenelabs.com

Founders:

Akpeli Nordor, Arthur de Garidel

Number of Employees:

11-50

Last Funding Date:

2023-09-29

IPO Status:

Private

Industries:

© 2025 bioDAO.ai